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ABSTRACT
Acute myeloid leukemia-initiating cells (LICs) are responsible for the emergence of leukemia and re-
lapse after chemotherapy. Despite their identification more than 15 years ago, our understanding of
the mechanisms responsible for their self-renewal activity and their chemoresistance remains poor.
The slow progress in this area is partly due to the difficulty of studying these cells ex vivo. Indeed,
current studies are reliant on xenotransplantation assays in immunodeficient mice. In this paper,
we report that by modeling key elements of the bone marrow niche using different stromal feeder
layers and hypoxic culture conditions, we can maintain LICs over at least 3 weeks and support their
self-renewal properties demonstrated through primary and secondary successful xenograft. We pro-
vide a proof of principle that this niche-like culture system can be used to study LIC chemoresistance
following in vitro cytarabine treatment similarly to the xenograft chemotherapy model. We found
that although LICs are believed to be more chemoresistant than non-LICs, functionally defined LICs
are not enriched after cytarabine treatment, and heterogeneity in their resistance to treatment
can be seen between patients and even within the same patient. We present a culture system that
can be used as an in vitro surrogate for xenotransplantation and that has the potential to dramatically
increase the throughput of the investigation of LICs. Thiswould further provide themeans bywhich to
identify and target the functionality of the different signaling pathways involved in the maintenance
and resistance of LICs to improve acute myeloid leukemia treatments. STEM CELLS TRANSLATIONAL
MEDICINE 2014;3:520–529
INTRODUCTION
Acutemyeloid leukemia (AML) is characterized by
the infiltration of leukemic myeloid blasts in the
bone marrow that have been arrested at various
maturation steps. Although 50%–75% of patients
respond to induction chemotherapy and enter re-
mission, the majority relapse, and only 20%–30%
of patients can achieve long-term survival [1].
One established paradigm of leukemogenesis is
that leukemia arises from themalignant transfor-
mation of a single cell and ismaintainedby a small
populationof leukemia-initiating cells (LICs) [2, 3].
It is commonly admitted that LICs are typically
chemoresistant due to intrinsic and extrinsic pro-
perties [4]. Efficient DNA repair pathways, high
levels of drug efflux pumps, and quiescence ac-
count for intrinsic drug resistance, whereas
environment-mediated drug resistance arises from
a complex interplay between soluble factors and cell
adhesion-mediated drug-resistance mechanisms
[5, 6]. Chemoresistant LICs are responsible for
AML relapse and represent the targets for future
innovative therapies [7].
Techniques currently available for culturing
primary AML samples have been adapted from
standardized protocols for culturing normal he-
matopoietic cells. Although in vitro short-term
liquid culture and colony assays allow quantifica-
tion of leukemic precursors, the identification of
LICs is still dependent on in vivo xenograft assays
in which LICs can self-renew and have the ability
to recapitulate the disease. Although new immu-
nodeficient mice strains and xenograft chemo-
therapy protocols are being defined [8], the
AML xenograft assay still requires a time frame
of 8–20 weeks before analysis and remains pro-
spectively blindwith little ability tomonitor prog-
ress. These limitations make its use difficult for
routine drug screening and investigation of the
role of specific genes and pathways involved in
LIC maintenance. The recently established LIC
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phenotype heterogeneity [9–12] and the lack of a reliable and
easy in vitro bioassay for monitoring LICs is slowing down the de-
velopment of innovative therapeutic strategies. Different cocul-
ture systems achieving some degree of support of normal or
leukemic hematopoiesis over a few weeks have been described
[13–17]; however, only a few of these studies truly demonstrated
the maintenance of normal hematopoietic stem cells (HSCs) val-
idated in parallel through xenotransplantation assessment. In the
context of leukemia, leukemic cobblestone area-forming cells
and/or leukemic long-term culture initiating cells (L-LTC-ICs)
can bemaintained for a fewweeks in coculture [18, 19]; however,
so far, there have been no reports demonstrating the ex vivo
maintenance of LICs through subsequent xenograft assessment.
Consequently, in vitro studies investigating environment-
mediated drug resistance have never been applied to human pri-
mary LICs.
A primary goal of establishing long-term cultures (LTCs) for
HSCs or LICs has been to mimic the bone marrow microenviron-
ment ex vivo. Cytokines and extracellular matrix proteins have
been shown to play an essential role in providing a supportive en-
vironment, but HSCs or LICs are also influenced by cues provided
through cell-cell contact (the “stem cell niche synapses”) be-
tween different cell types in the bonemarrowmicroenvironment
such as preosteoblasts, osteoblasts, endothelial cells, andmesen-
chymal cells [20–24]. In the leukemic context, survival and prolif-
erative benefits have been reported for primary AML samples
when coculturedwith the osteosarcoma SaOS-2 or human umbil-
ical vein endothelial cell (HUVEC) lines [25–28]. A mesenchymal
MS-5 coculture supplemented with interleukin 3 (IL3), granulo-
cyte colony-stimulating factor (G-CSF), and thrombopoietin
(TPO) can also sustain primary AML samples over 24 weeks with
successful generation of leukemic cobblestone area-forming cells
andprimary L-LTC-ICs [18]; however, it is not knownwhether all of
these coculture systems can actually sustain LICs. Hypoxia is
also known to favor normal HSC quiescence and maintenance,
whereas normoxia induces proliferation and differentiation, fol-
lowed by exhaustion [29–31]. In AML, a recent study has demon-
strated a requirement for the hypoxia-inducible factor 1a
pathway for LICmaintenance in vivo [32]. The impact that hypoxia
has onAML survival in steady-state condition or under drug treat-
ment is less clear, depending on the population of cells and the
drug being studied [33–35]. Furthermore, the chemoprotective
role of hypoxia in LICs in vitro remains to be explored.
Our work represents the first direct comparison between dif-
ferent coculture systems and the assessment of the impact of low
oxygen on functionally defined human LICs. This was achieved by
secondary leukemia-long-term culture and in vivo repopulating
assays in limiting dilution. We report a reliable, easy, and repro-
ducible niche-based culture system suitable for the maintenance
of human primary LICs. In addition, we show that this system
could be used to study the chemoresistance of LICs and to screen
the activity of new therapeutic agents that will specifically target
and eliminate LICs.
MATERIALS AND METHODS
Cells
AML cells were obtained after informed consent at St. Bartholo-
mew’s Hospital (London, U.K.). The protocol was approved by the
East London Ethical Committee and in accordance with the
Declaration of Helsinki. Samples were collected at diagnosis
and first screened for their ability to engraft in immunodeficient
mice. Details of the patient samples are listed in supplemental
online Table 1. The stromal cell line MS-5 was obtained from
the DSMZ cell bank (Braunschweig, Germany, http://www.
dsmz.de) and maintained in Iscove’s modified Dulbecco’s me-
dium (IMDM) plus 10% fetal calf serum plus 2 mM L-glutamine.
Short-Term Culture, LTC, and Secondary Plating LTC
Cocultures were performed as bulk culture or using a limiting di-
lution analysis on confluentmonolayer ofMS-5, supplemented as
indicated with recombinant human IL3, G-CSF, and TPO (MS-51
3GT) (20 ng/ml each; Peprotech, London, U.K., http://www.
peprotech.com) in MyeloCult H5100 (StemCell Technologies,
Vancouver, BC, Canada, http://www.stemcell.com). Cells were
cultured at 37°C in 5% CO2 -humidified incubators at 20% or 3%
O2 conditions. Low-oxygen cultures were performed in a two-gas
HERAcell incubator (Thermo Fisher Scientific, Waltham, MA,
http://www.thermoscientific.com/en/home.html). For cyto-
sine b-D-arabinofuranoside (Ara-C; Sigma-Aldrich, St. Louis, MO,
http://www.sigmaaldrich.com) treatment, AML cells were prein-
cubated in coculture 72 hours prior to the addition once of
Ara-C at 3mMfollowed by an additional 7 days of culture. In some
experiments, cocultureswerewashed four timeswith phosphate-
buffered saline after Ara-C treatment, and then fresh MyeloCult
H5100 medium was added, and cocultures were maintained for
two additional weeks. For primary LTC for limiting dilution anal-
ysis (LDA; 1° LDA) and secondary LTC for LDA (2° LDA), cells were
plated in20 replicates in96-wellmicroplates containing confluent
MS-5 monolayer. After 5 weeks, LTC medium was replaced by
methylcellulose H4435 (StemCell Technologies). After an addi-
tional 2 weeks, each well was scored as negative if no colonies
were present. All 2° LDA and colony assays were performed in
normoxia. To determine the frequency of L-LTC-ICs, LDA was
done using LCalc software (StemCell Technologies) according
to the Poisson statistics and method of maximum likelihood.
Flow Cytometry Analysis
Fluorescence-activated cell sorting (FACS) analysis was performed
withaBDLSRII flowcytometer, and cell sortingwasperformedwith
a BD FACSAria (BD Biosciences, San Diego, CA, http://www.
bdbiosciences.com). After 1–5 weeks of coculture, nonadherent
and adherent cells were harvested through trypsinization. Recov-
ered cells were resuspended and stained in Annexin-binding buffer
(BD Biosciences). Sca-1was identified as a specificmarker for 100%
of MS-5. Human hematopoietic cells were stained with anti-CD45-
APC-Cy7, anti-CD34-Percp, anti-CD38-PE-Cy7 antibodies, and Lin-
FITC as well as with Alexa Fluor 647-conjugated Annexin V (Invitro-
gen, Carlsbad, CA, http://www.invitrogen.com). At the end, cells
were resuspended in phosphate-buffered saline containing 49,6-
diamidino-2-phenylindole (DAPI). All antibodies were from BD Bio-
sciences. Only viable (both DAPI and Annexin V-negative fraction)
human hematopoietic cells (CD45-APC-Cy7 positive and Sca-1-PE
negative) were assessed and/or sorted for all analyses. For some
AML samples, LIC and non-LIC phenotypes were used according
to pre-established xenograft experiments with sorted subpopula-
tions (previouslypublished in [10] anddatanot shown). For thepre-
cise cell counts, CountBright absolute counting beads (Molecular
Probes, Paisley, U.K., http://probes.invitrogen.com) were used
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to assess the total number of cells, following manufacturer’s
recommendations.
Adoptive Transfer of Human Hematopoietic Cells in
Immunodeficient Mice
All animal experiments were performed in compliance with
Home Office and Cancer Research UK guidelines. NOD/SCID/b2-
microglobulin null (b2m
2/2)mice or NOD/SCID IL-2Rg common
chain null (NSG) were originally obtained from Dr. Leonard
Schultz (Jackson Laboratory, Bar Harbor, ME, http://www.jax.
org) and bred at the animal facility of the London Research Insti-
tute. Mice were irradiated at 375 cGy (137Cs source) 24 hours be-
fore transplantation. The same mouse strain (b2m
2/2 or NSG)
was used to address one experimental parameter per patient.
Cells were injected via intratibia injection because of previous re-
port of an HSC homing defect described after in vitro manipula-
tion [36]. MS-5 cells were eliminated by cell sorting prior to cell
inoculation.Animalswere sacrificedat12weeks, andbonemarrow
cells were collected from the injected bone and contralateral non-
injected long bones separately. For LDA experiments, cell doses of
102 to 107 cells from primary AML samples were injected into
three to five recipients per dose.Amousewas scoredasengrafted
if a distinct human CD45+ and murine CD452 population was de-
tectable in the contralateral bone marrow. AML engraftment
was defined by the presence of a single CD45+CD33+CD192
population.
Please refer to the supplemental online data for the remain-
ing materials and methods information.
RESULTS
Selection of Feeder Layer andOxygen Concentration for
AML Initiating Cell Maintenance In Vitro Over 3 Weeks
Based on the heterogeneity of AML, we first aimed to compare
osteoblasts and endothelial andmesenchymal coculture systems
with a large number of AML samples at 20% O2. Therefore, we
evaluated the cell viability of 38–57 AML samples (sup-
plemental online Table 1) after coculturing them for 1 week with
mesenchymal-related MS-5, osteoblast-derived SaOS-2, and en-
dothelial HUVEC lines without cytokine supplement. We ob-
served a highly variable level of cell viability, ranging from
3.23% to 96.4%, but this variability was seen across the three sys-
tems. This was in contrast to normal HSCs and hematopoietic
stem/progenitor cells, in which we observed a homogenous cell
viability of 84%6 8% (p, .001, n = 16; data not shown) during
coculture. A cross-comparison analysis for each individual AML
sample revealed that MS-5 was the most supportive coculture
system (Fig. 1A). Furthermore, with the MS-5 condition, we also
observed maintenance of the cell number (with a mean fold ex-
pansion of 1.22 6 0.32; 28 samples). Phenotypic analysis also
revealed MS-5-based coculture as the most efficient system for
keeping the initial CD34 and CD38 expression pattern, as com-
pared with SaOS-2 or HUVEC, with which CD34+ cells were de-
creased and CD38+ cells were increased (Fig. 1B). Thus, we
focused on the MS-5 feeder because it appeared to be the most
efficient system for supporting leukemic cells. A previous report
demonstrated that MS-5 supplemented with IL31G-CSF1TPO
(MS-513GT) allows the expansion of leukemic cells [18]. Thus,
Figure 1. One-week coculture onmesenchymal-relatedMS-5 cells promoted better AML cell viability and better retained the initial phenotype
compared with osteoblast-derived SaOS-2 and endothelial-like HUVEC. (A): Viability comparison, MS-5 and sample 12 (57 samples), MS-5 and
HUVEC (38 samples), and SaOS-2 and HUVEC (43 samples). Putative equivalent cell viability is represented by the bold black line. The thin black
line showsexperimentally derived simple linear regression trend linewith the95%confidenceband (dashed lines). Apaired t testwasapplied for
each comparison. (B): Fluorescence-activated cell sorting plot of CD34 and CD38 expression profiles of a CD34+ representative AML sample
(sample6) just after thawing (leftpanel)orafter1-weekcoculturewithMS-5, SOS-2,orHUVECs.A49,6-diamidino-2-phenylindole-negative/Annexin
V-negative population was used for analysis. Numbers represent the percentages of cells within each region. Abbreviations: AML, acute myeloid
leukemia; HUVEC, human umbilical vein endothelial cell.
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the impact of the 3GT cytokine cocktail was next investigated. Af-
ter 3 days in suspension culture, 3GT alone did not increase the
post-thawed viability of AML cells; however, the MS-5+3GT con-
dition increased viable cells by 18.8% 6 5.7% (n = 23, p , .005)
(supplemental online Fig. 1A). AML long-term cocultures per-
formed with or without 3GT also demonstrated a requirement
of cytokine supplement for the maintenance of L-LTC-ICs over
a 5-weekperiod (supplemental online Fig. 1B). Preliminary results
obtained with few patients among the ones presented in this
studywere also cultured for 5weeks. In contrast to normal hema-
topoietic stem/progenitor cells, there was no clear benefit in
terms of leukemic pool expansion going from 3weeks to 5 weeks
(data not shown); therefore, all subsequent experiments were
shortened to 3 weeks.
Of note, all the AML samples used for the rest of this study
were pre-evaluated for their capacity to give rise to an exclusive
leukemic engraftment (verified by a unique high-scatter
CD45+CD33+CD192 myeloid blast population by flow cytometry
analyses). We further confirmed the leukemic origin of the cells
after ex vivo culture. For patientswith nucleophosminmutations,
for example, we show by polymerase chain reaction that nucleo-
phosmin mutation can be detected in the cells after culture
(supplemental online Fig. 1C). Furthermore, in the read-out
colony-forming unit assay, we observed only blast-type colony for-
mation, thus excluding the possibility of having expanded normal
hematopoietic cells.
Wewere then interested in the impact of the 3%O2 condition
on AML cells in vitro. Primary AML cells showed a significant de-
crease in growth when cultured at 3% O2 compared with 20% O2
(p, .05) (Fig. 2A). We quantified the replating potential of three
AML samples maintained for 3 weeks either in 3% O2 or 20% O2
compared with day 0 (Fig. 2B). We observed 2.7-, 4.5-, and 1.96-
fold increases in L-LTC-IC frequencies in 2° LDA for sample 6
(p, .005), sample 2 (p, .0001), and sample 3 (p, .05), respec-
tively, when cultured at 3% O2 compared with 20% O2 (Fig. 2C).
When comparing the initial L-LTC-IC frequency (1° LDA, day 0)
with the frequency after the3weeksof culture (2° LDA) and taking
into account the fold expansion, we were able to determine the
Figure 2. Low oxygen concentration favors long-term in vitro maintenance of leukemia-initiating cells (LICs) over 3 weeks. (A): 3%O2 reduced
AML expansion. AML samples were cocultured for 3weeks withMS-5+3GT at 20%O2 or 3%O2 in parallel. Data shown represent fold expansion
of fiveAMLsamples (samples 2, 7, 10, 3, and6)determined in20%O2or3%O2.p,p, .05 inpaired t test. (B): Flowchart illustrates theexperiment
design for (C) and (D). (C): Replating potential at week 3. Cells fromAML samples 6, 2, and 3were cocultured at 20%O2 or 3%O2 for 3weeks and
then sorted for CD45+ cells and replated in 2° LDA for an additional 5 weeks at 20% O2. (D): Total L-LTC-IC numbers calculated from 1° LDA and
2° LDA after 3 weeks of coculture at 20% O2 or 3% O2 for samples 6, 2, and 3. p, p, .05; ppp, p, .001; NS, p. .05 (90% confidence interval is
displayed). (E): Flowchart illustrates the experiment design for (F) and (G). (F): In vivo LDA of cells from AML samples 6, 2, and 3 recovered from
each coculture and injected at different doses intoNOD/SCID interleukin-2Rg commonchainnullmice (for sample 6,n=24, and sample 3,n=42)
or NOD/SCID/b2-microglobulin nullmice (for sample 2, n = 52) to calculate the frequency of LICs. (G): Total LIC counts (90% confidence interval)
determined for cells fromsamples 6, 2, and3 for uncultured (T0) or cocultured cells for 3weeks at 20%O2or 3%O2.p,p, .05;NS,p. .05. For (D)
and (G), data presented take into account the fold expansion in culture. (H): Primary and secondary leukemic engraftment in NOD/SCID/b2-
microglobulin null mice of AML samples cocultured for 3 weeks. The data show the percentage of human leukemic chimerism in primary re-
cipient mice (first) for six samples (samples 1, 2, 3, 4, 5, and 6) and secondary recipients (second) for samples 1, 2, and 3. Plain lines represent
mean levels of leukemic cell engraftment in each group. Each symbol represents a single transplanted mouse. Abbreviations: 1° LDA, LDA from
post-thawed cells; 2° LDA, LDA fromcultured cells; AML, acutemyeloid leukemia; CFC, colony forming cells; LDA, limiting dilution analysis; L-LTC-
IC, leukemic long-term culture initiating cell; NS, not significant; w, weeks.
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difference between the total L-LTC-IC input and output numbers.
In 20% O2 coculture, L-LTC-ICs capable of secondary plating were
found to be either decreased (sample 6), maintained (sample
2), or increased (sample 3) compared with their respective input
numbers (Fig. 2D). A low-oxygen coculture systemwas foundben-
eficial for samples 2 and 3 in terms of total L-LTC-IC number,
whereas a decrease was observed for sample 6 compared with
their respective inputnumbers. Altogether, low-oxygen coculture
appears to be superior to the 20% O2 coculture condition.
Xenograft Potential Maintenance After Ex Vivo Culture
Wethenwonderedwhether the invitroL-LTC-IC replatingpotential
observed was indicative of LIC activity. In vivo LDA was performed
for these three samples after coculturing either at 20%O2 or 3%O2
for 3 weeks (Fig. 2E). Leukemic (myeloid-restricted) engraftment
was observed in all cases (supplemental online Fig. 3). There were
138.8-, 6.5-, and 4.7-fold increases in LIC frequency at 3% O2 com-
pared with 20% O2 for samples 6, 2, and 3, respectively (Fig. 2F)
(p, .0001). We also determined for samples 6, 2, and 3 the total
LIC input and output numbers. For samples 6 and 2, the 3% O2 co-
culture condition allowed for maintenance of LICs compared with
their initial input number, whereas significant 57.3- and 6.1-fold
decreaseswere obtained, respectively, in the normoxic culture sys-
tem (p, .05) (Fig. 2G). For sample 3, we observed a reduction in
total LICs after culture compared with day 0, and this change
appears to be independent of the culture conditions used (3%
O2 vs. 20% O2) (Fig. 2G). To further validate the beneficial impact
of the low-oxygen coculture system, we repeated the experiments
(3weeksat3%O2)withanadditional sixprimaryAMLsamplesprior
to transplantation into NOD/SCID/b2m
2/2mice. In six of nine sam-
ples tested (including samples 6, 2, and 3, already presented), leuke-
mic myeloid-restricted engraftment could be detected after culture
at 3% O2 (Table 1). In three of these six samples, self-renewal
Table 1. LIC frequency is retained over 3 weeks of in vitro coculture with MS-513GT at 3% O2
AML
samplesa
One LIC per injected
cell number before
culture (range)
Fold expansion
(6SEM for n cultures)
Dose injected
after culture
Number of
leukemic engrafted
mice/number of
mice analyzed
One LIC per injected cell,
number after culture (range)
1 335,107 (201,948–556,067) 0.5806 0.3 (n = 5) 20,000 0/1 489,267 (279,919–855,183)
46,000 0/1
500,000 14/19
2 175,966 (76,016–407,337) 0.6786 0.196 (n = 4) 200 0/4 162,570 (80,320–329,046)
2,000 1/3
11,500 1/1
20,000 3/5
100,000 3/3
200,000 4/4
535,000 3/3
4,800,000 3/3
3 2,876 (991–8,351)b 0.135 750 0/3 3,846 (7,972–1,856)b
1,500 1/6
3,000 4/6
10,000 3/3
30,000 3/3
4 13,650 (28,609–213,248) 0.3 500,000 22 ND
5 ND 5.42 116,000 0/1 ND
1,300,000 3/3
6 3,007 (1,160–7,791)b 0.696 0.51 (n = 2) 1,500 1/2 1,231 (398–3,808)b
3,000 3/3
10,000 3/3
30,000 3/3
794,000 4/4
7 2,229,695 (1,006,989–4,937,033) 8.4 500,000 0/8 ND
ND 1,000,000 0/9
8 .5,000,000 0.176 0.05 (n = 2) 60,000 0/4 ND
100,000 0/2
10 7,663,450 (4,036,119–14,550,727) 2,775 3,000,000 0/6 ND
aSample characteristics are found in supplemental online Table 1.
bXenograft performed in NOD/SCID/b2-microglobulin null or NOD/SCID interleukin-2Rg common chain null mice.
Abbreviations: LIC, leukemia-initiating cell; ND, not determined.
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capacity was also investigated by performing serial transplants,
and leukemic engraftment was observed in all secondary recipi-
ents (Fig. 2H; supplemental online Fig. 3). To further investigate
the engraftment failure observed in three patients after culture
(samples 7, 8, and 10), we evaluated the LIC frequency before
in vitro culture (Table 1). We found that these samples had the
lowest LIC frequency of the patients analyzed and that the cells
injected after culture fell below the initial LIC frequency observed
in noncultured cells. Altogether, these results support the notion
that functionally defined LICs can be maintained in vitro over
a 3-week period in MS-5+3GT at 3% O2 but not at 20% O2.
Chemoresistant LICs Can Be Studied In Vitro
We next investigated whether these culture conditions might be
suitable for studying chemoresistance of LICs to cytarabine (Ara-
C), a commonly known drug for AML treatment. We decided to
use Ara-C at a concentration of 3 mM, which is.25 times higher
than the IC50 dose obtainedon threeAMLcell lines (supplemental
online Fig. 2A) but 3.8 times lower than the IC50 dose for MS-5
feeder cells. We selected this dose because it was safe for the
MS-5 stroma cells used, andwewished to evaluate the chemore-
sistance of LICs. After 7 days with Ara-C treatment in normoxic
conditions, we observed more than 94% eradication of primary
leukemic cells in both suspension and MS-5-based culture sys-
tems (supplemental online Fig. 2B1). However, coculture on
MS-5 improved the percentage of viable cells fourfold in the re-
sidual population for leukemic samples compared with the sus-
pension system (p , .05) (supplemental online Fig. 2B2). We
observed that culturing the cells at 3% O2 improved the recover-
able fraction of live leukemic cells after Ara-C treatment (Fig. 3A,
3B). When replating live cells after Ara-C-treated groups cultured
under 3%O2 or 20%O2 (Fig. 3C), we observed that cells that were
able to reinitiate leukemic LTC were enriched in the 3% O2 group
(Fig. 3D) by 34-fold for sample 6 (p, .0001) and 3-fold for sample
2 (p, .01). More important, a chemoprotective effect of low ox-
ygen was also observed when looking at the total yield of L-LTC-
ICs in secondary plating for these samples: 32 times and 3 times
more secondary L-LTC-ICs were recovered in 3% O2 cultures (Fig.
3E) for sample6 (p, .01) and sample2 (p, .05), respectively.We
further demonstrated that residual cells were still capable of
engrafting immunodeficient mice. However, cultures at 3% O2
without any feeder layer did not support the engraftment of cells
that remained after Ara-C treatment (no MS-5), demonstrating
that the maintenance of LICs required stroma support for their
chemoresistance under 3% O2 (Fig. 3F).
Figure 3. Low oxygen concentration enhances in vitro chemoresistance of AML cells in coculture and allows the preservation of leukemia-
initiating cell activity. (A): Flowchart shows the experiment design for (B). (B): Data represent mean percentage (6SEM) of four AML samples
(samples 2, 3, 6, and 10) retrieved after 1week of ARA-C at 3mMcomparedwith untreated control cells countswhen coculturedwithMS-5+3GT
at 20%O2 or 3%O2. (C): Flowchart shows the experiment design for (D) and (E). (D): Replating potential after ARA-C treatment. Cells from AML
samples 2 and 6were treated during the first weekwith 3mMARA-C in cocultures at 20%O2 or 3%O2. Cocultures werewashed andmaintained
for an additional 2 weeks. Viable leukemic cells were sorted in week 3 and then replated in 2° LDA for an additional 5 weeks. (E): Total leukemic
long-term culture initiating cell numberswere calculated from1° LDA of uncultured cells and 2° LDA of 3-week cultured and ARA-C-treated cells
at 20%O2 or 3%O2 for samples 6 and 2. ARA-C treatment occurred during the first week only. Data presented take into account the first culture
foldexpansion.p,p, .05;pp,p, .01;ppp,p, .001. (F):Cells fromAMLsample 1were coculturedwithMS-5+3GTor cultured in suspensiononly
with 3GT (noMS-5) in the presence of 3mMARA-C at 3%O2. Recovered live cellswere sorted for humanCD45
+ cells at 3weeks and then injected
into NOD/SCID interleukin-2Rg common chain null mice (n = 8). We injected 53 104 cells, which represented 17% of the input cell number for
theMS-5 condition and 23% for the noMS-5 condition. Data shown represent the percentage of human leukemic engraftment in recipient bone
marrow determined by fluorescence-activated cell sorting analysis at 12weeks after injection. Solid lines representmean levels of leukemic cell
engraftment in each group. Dashed lines represent the threshold of positivity. Each symbol represents a single transplantedmouse. p, p, .005.
Abbreviations: 1° LDA, limiting dilution analysis frompost-thawed cells; 2° LDA, limiting dilution analysis fromcultured cells; AML, acutemyeloid
leukemia; ARA-C, cytosine b-D-arabinofuranoside; MS-5, MS-5+3GT; NO MS-5; no MS-5+3GT; w, weeks.
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In Vitro Ara-C Treatment Does Not Enrich for LICs
In the dose tested, Ara-C treatment was really effective at killing
leukemic cells in vitro (Fig. 4A; supplemental online Fig. 2B1). Be-
cause LICswere reported tobequiescent [37],wewondered if the
in vitro Ara-C treatment could preferentially kill non-LIC blasts,
hence enriching for LICs. For seven AML samples, the CD34/CD38
phenotype appeared globally unchanged after Ara-C treatment,
despite the drastic impact of Ara-C on reducing the cell number
(Table 2; supplemental online Fig. 4). For five AML samples, we
functionally determined the phenotype of the LIC compartment
before treatment in vivo (Table 2). As recently published by our
group and others [9–12], LIC phenotype was not restricted to
Figure 4. Chemoresistant LIC maintenance can be assessed through in vitro replating potential. (A): Histograms represent the percentage of
viable CD45+ cells counts at 1 week (6SEM ; n = 3) for four AML samples (samples 3, 2, 1, and 6) cocultured withMS-5+3GT at 3%O2with 3mM
ARA-C compared with untreated (100%) control. (B): The percentage of LICs versus non-LICs was determined by fluorescence-activated cell
sorting for five AML samples (samples 1, 2, 6, 7, and 10) before and after ARA-C treatment. Data represent the frequency of LICs and non-LICs
in the ARA-C condition compared with control untreated. Values shown were normalized to the respective untreated condition, and error bars
are6SEM. Refer to Table 2 and to theMaterials andMethods for LIC and non-LIC population definitions. NS, p. .05. (C): Flowchart illustrating
the experimental design for (D–G). (D): L-LTC-IC frequencies in secondary plating relative to control were calculated during LDA with cultured
cells.Untreatedor in vitroARA-C-treated samples 3, 2, and6are shown. (E):Xenograft potential ofAMLcells after ex vivo chemotherapy. A single
cell dose (20,000 cells; samples 3, 2, and 6) of sorted leukemic cellswere injected intoNOD/SCID interleukin-2Rg common chain null (NSG)mice.
Scatter plot represents leukemic engraftment in recipient bonemarrowat 12weeks after injectionwithuntreated cells or in vitroARA-C-treated
cells. Each symbol represents a single transplantedmouse. ppp, p, .001; NS, p. .05. (F): In vivo LDA for sample 2. Untreated or in vitro ARA-C-
treated cellswere injected at LDA intoNSGmice, and LIC frequencywas calculated (22mice). (G): Total LIC numbers calculated for sample 2were
derived from transplantation data using NSG mice. Culture fold expansion was taken into account. ppp, p, .001; NS, p. .05. (H): Flowchart
illustrating the in vivoARA-C treatment. (I):Atweek 12, after establishing leukemia inNSGmicewith samples 3, 2, and 6, recipientswere treated
with ARA-C (10mg/kg per day) for 7 days. Data show themean absolute number of leukemic cells on day 7 in the first recipient mice treated or
notwithARA-C (ppp,p, .001;p,p, .05). (J): LDA in secondaryNSGmice after in vivoARA-C treatment inprimary recipients for samples 3 and2.
Cells from the first recipients were sorted and injected into secondary recipients at LDA to calculate the frequency of LICs. (K): Data shown
represent leukemic engraftment in NSG mouse bone marrow after secondary xenotransplantation of indicated cell doses from sample 6 cells
recovered from primary recipient. NS, p . .05. Abbreviations: AML, acute myeloid leukemia; ARA-C, cytosine b-D-arabinofuranoside; CT, un-
treated; L-LTC-IC, leukemic long-term culture initiating cells; LDA, limiting dilution analysis; LIC, leukemia-initiating cell; NS, not significant; w, weeks.
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the CD34+CD382 population. When comparing the proportion of
defined LIC and non-LIC fractions before and after treatment, we
did not observe any significant enrichment of LICs after treatment
(Fig. 4B).
Nevertheless, to further confirm the persistence of L-LTC-ICs
in the residual Ara-C-treated population, we performed 2° LDA to
determine the frequency of L-LTC-ICs capable of secondary plat-
ing (Fig. 4C, 4D). We saw a 3.5- and 8.7-fold decrease of L-LTC-IC
frequency in theAra-C condition for samples 3and2, respectively,
whereas for sample 6, the frequency was not altered. To evaluate
the correlation between L-LTC-ICs capable of secondary plating
and LICs, we first injected the same cell dose (control and Ara-C
group) in NSG mice and observed a reduction in the level of en-
graftment with Ara-C treatment compared with control for sam-
ples 3 and 2, whereas for sample 6, similar engraftment was
observedwithAra-C treatment and control (Fig. 4E). These results
mimic the in vitro L-LTC-IC results. We further performed an in
vivo LDA for sample 2, and that allowed us to calculate the fre-
quency and the total number of LICs after culture with or without
Ara-C. We found a 16-fold reduction in the LIC frequency after
treatment (p, .01) (Fig. 4F) and a 460-fold reduction of the total
number of LICs (p , .01) (Fig. 4G). Interestingly, comparable 8-
fold and 313-fold reductions in secondary L-LTC-IC frequency
and total number, respectively, could also be observed through
2° LDA (both p, .0001) (Figs. 2E, 4D). Our data show that simply
determining in vitro killing or performing phenotype analysis
were not informative parameters for assessing drug-targeting
efficiency toward LICs versus non-LICs, whereas the 2° LDA
was as efficient as the xenograft assay to interrogate LIC
persistence.
Comparative Effect of Ara-C on LICs Treated Ex Vivo and
In Vivo
To determine whether the in vitro Ara-C treatment in our culture
condition would reproduce an in vivo chemotherapy treatment
protocol,we compared the impact of the two treatmentson three
AML samples (samples 3, 2, and 6). Twelve weeks after establish-
ing leukemia in NSGmice, one group of animals was treated with
Ara-C (at 10 mg/kg for 1 week) and sacrificed at the end of the
treatment (Fig. 4H). We observed a mean leukemic burden that
was 4 times lower (sample 3), 17 times lower (sample 2), and
2.53 times lower (sample 6) in the treated group (Fig. 4I). To look
at the impact on LICs, we performed an LDA in a secondary trans-
plant setting. We could determine the LIC frequency. and we
found 4.7- and 6.9-fold reductions in the LIC frequency for sample
3 (p, .05) and sample 2 (p, .01), respectively, after treatment
(Fig. 4J). In contrast, in all three doses tested for sample 6, we did
not observe any difference between the control and Ara-C-
treated groups, indicating that, at least for this patient, the LIC
compartment was not significantly affected during the in vivo
Ara-C treatment (Fig. 4K). These results show a good correlation
between in vitro and in vivo treatment of cellswithAra-C.Wepro-
pose that L-LTC-ICs in secondary cultures (2° LDA) could serve as
Table 2. Impact of 1 week of Ara-C treatment on CD34 and CD38 subpopulations
AML samples Condition
Ara-C impact, control
cell count (%)
Population (%)
CD34+CD38+ CD342CD38+ CD34+CD382 CD342CD382
2 CT 100 0.01a 0.408a 98.40b 1.28b
Ara-C 4 0.02 1.38 95.50 3.22
Ara-C /CT ratio 0.04 1.60 3.38 0.97 2.51
1 CT 100 0.11b 0.701b 73.9a 26.1b
Ara-C 6.60 0.11 0.731 80.9 19.1
Ara-C /CT ratio 0.06 1.00 1.04 1.09 0.73
3c CT 100 0.00 0.06 91.2 8.73
Ara-C 3.7 0.00 0.08 90.8 9.11
Ara-C /CT ratio 0.04 1.37 0.99 1.04
11c CT 100 0.53 3.74 66 29.7
Ara-C 6.7 0.58 1.58 65.5 32.4
Ara-C /CT ratio 0.07 1.09 0.422 0.99 1.09
6 CT 100 0.368b 29.7b 63.4a 6.52a
Ara-C 10.8 0.433 24.6 66.1 8.93
Ara-C /CT ratio 0.11 1.17 0.82 1.04 1.37
10 CT 100 0.68, ND 15.1b 82.7a 1.65a
Ara-C 0.26 0.91 39.1 56.4 3.64
Ara-C /CT ratio 0.003 1.34 2.59 0.68 2.21
7 CT 100 11.4b 76.3b 11.5a 0.83a
Ara-C 41.36 12 86.2 1.56 0.191
Ara-C /CT ratio 0.41 1.05 1.13 0.13 0.23
aGate devoid of LIC activity.
bGate enclosing LICs.
cSample not tested for subpopulation xenograft potential.
Abbreviations: Ara-C, cytosine b-D-arabinofuranoside; CT, untreated; LIC, leukemia initiating cell; ND, not determined, gate not tested for xenograft
potential.
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a good surrogate assay for the xenotransplantationmodel, allow-
ing screening of LICs affecting drugs in vitro.
DISCUSSION
In this study, we have defined the MS-5+3GT 3% O2 culture con-
dition as an efficient niche-like culture system tomaintain human
LICs in vitro.
A recent study demonstrated a requirement for the hypoxia
signaling pathway for LIC maintenance in vivo [32]. Our data sup-
port these results and further demonstrate that hypoxic condi-
tions are also essential for LIC maintenance ex vivo. Culturing
AML on MS-5+3GT at 3% O2 for 3 weeks preserved the LIC fre-
quency and maintained the total number at the initial level. By
using serial transplantation, we were also able to demonstrate
that LIC self-renewal potential was preserved during the 3-week
coculture period.Myeloid-restrictedmouse engraftmentwas ob-
served in all cases, indicating that the residual normal HSCs that
could have been present within leukemic samples did not out-
compete the AML cells during ex vivo culture, contrary to what
has been described previously in other culture systems [19].
More important, we demonstrated that this niche-like culture
system is also capable of supporting functionally defined human
chemoresistant LICsasefficientlyas the invivoassay,withthe latter
beingamorecostlyandtime-consumingexperimentalapproach. In
a rare casewhereAML cells could be cultured in absenceof stroma
for 3weeks,wewere able todemonstrate that 3%O2 improved LIC
chemoresistance in a feeder-dependent fashion. Our study also
shows thatphenotypic analysis of treatedAML cells is an inefficient
method for determining the LIC targeting efficacy. Recent studies
from our laboratory and others demonstrate the LIC surface anti-
gen phenotype is more heterogeneous than initially believed [9–
12]. In this study, our effort to identify the actual LIC phenotype
persamplebycouplingheavysortingstrategieswith thexenotrans-
plantation assay proved to be a useless approach in the context
of cytarabine treatment because the CD34 and CD38 expression
profile was not perturbed. Alternatively, we repeatedly observed
that quantifying the frequency of L-LTC-ICs in secondary cultures
(2° LDA) is a reliable functional read-out for monitoring the LICs.
The 2° LDA or xenograft LDA also proved that LICs are not system-
atically enriched after chemotherapy, whereas the total leukemic
pool is effectively decreased after Ara-C, at least for the samples
tested. Although further samples should be investigated to cover
AML heterogeneity, our observations suggest—contrary to con-
ventional belief—that LICs do not always preferentially survive an-
tineoplastic treatment compared with non-LICs. Because our
1-week Ara-C treatment mimics the clinical treatment duration,
we believe that our experimental setting represents a goodmodel
fordissecting the sequenceofmolecularmechanismsbywhichLICs
escape cell death. Although this ex vivo system is faster and re-
quires less tissue material than the xenograft assay, our data also
demonstrate that its use might be limited to the most aggressive
samples, in which LICs are relatively frequent.
CONCLUSION
The 2° LDA read-out for L-LTC-ICs described in this paper could
represent the first system inwhich sensitivity to drugs, small com-
pounds, or short hairpin RNA library screening could be tested on
a relatively large scalewith LICs. This appears evenmore crucial in
the context of preclinical and clinical studies, which have demon-
strated that assessment of bulk tumor shrinkage is not faithfully
related to patient survival [38–40].Moreover, this tool should en-
able both pharmaceutical and academic research laboratories to
design innovative therapeutic approaches to target and monitor
the roots of AML.
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